Industry landscapes
The companies, capital and talent shaping healthtech in the United Kingdom. Find the leaders. Understand the segments. See where the activity is.
An industry ecosystem,
measured in context.
24 featured companies from the funding, hiring, revenue and team-size leaderboards.
Locked revenue figures are available in Radar; the eight company financial previews stay the same throughout this page. A dash means the figure is outside these featured lists. Revenue years vary by company; the figures are not a like-for-like revenue comparison. Compare annual accounts ↗
No company example met every recorded classification, independence and public-profile gate in this snapshot. The live directory may have newer qualifying companies.
Explore classified startups in Radar ↗A few useful ratios bring the size of this ecosystem into perspective.
183 of 5,682 tracked companies have open roles.
1,001 of 5,682 tracked companies have a recorded round.
Share of disclosed capital received by the three largest recorded recipients.
Midpoint of 1,935 rounds with a disclosed amount.
Scale is concentrated. Opportunity is broader. The three largest funding recipients hold 20.0% of disclosed capital, while 82.4% of tracked companies have no recorded funding round.
Explore the segments →Recorded company formation and disclosed funding across the complete annual series shown.
Sum of recorded funding rounds · USD
| Year | Funding (USD) | Founded | Raising |
|---|---|---|---|
| 2016 | $588.49M | 254 | 123 |
| 2017 | $549.61M | 303 | 137 |
| 2018 | $1.07B | 352 | 145 |
| 2019 | $1.75B | 419 | 177 |
| 2020 | $835.71M | 523 | 195 |
| 2021 | $2.53B | 327 | 233 |
| 2022 | $1.33B | 212 | 182 |
| 2023 | $953.48M | 221 | 153 |
| 2024 | $1.03B | 141 | 136 |
| 2025 | $1.15B | 63 | 106 |
Share of all disclosed company funding.
2,301 recorded rounds since 2016
Recorded participation in healthtech company rounds since 2016.
Backed by Innovateuk.
Backed by NLC.
Backed by Malta Enterprise.
Backed by Angelini Ventures and Heal Capital and others.
Backed by IW Capital and IP Group and others.
Backed by Salica Investments.
Backed by Guinness Ventures.
Backed by .
Backed by Ally Bridge Group and Railpen and others.
Backed by Kinnevik and Public Investment Fund and others.
Backed by Vanderbilt University and Kairos and others.
Backed by Escala Capital and Watrium and others.
Backed by Novo Holdings and BlackRock and others.
Backed by General Atlantic.
Backed by Ally Bridge Group and Cambridge Innovation Capital and others.
Backed by G Square and BGF.
Backed by BDT & MSD Partners and Schroders Capital and others.
Backed by Leaps by Bayer and Samsung NEXT and others.
Annual accounts for reporting companies linked to this landscape, on like-for-like currency and reporting bases.
Display conversions use the dated reference rates above. Where a verified rate is unavailable, figures retain their source currency. Each reporting cohort keeps its currency and accounting basis separate.
FY2025 · annual statements grouped by reported fiscal year; exact entity periods remain on preview rows · 24 reporting entities from 1647 eligible matches.
Sum of reporting-entity revenue; not the United Kingdom market sales.
Combined result for the same cohort.
Combined net income ÷ combined revenue.
The middle covered reporting entity.
16 of 24 covered entities.
Share of covered revenue from the five largest entities.
Reported cohort totals by year; coverage is stated for every period.
Bar height shows revenue. Changes in coverage can affect totals.
FY2025 · 24 reporting entities
Up to eight fixed company previews show financial amounts. Search and sort the wider company list, then continue in Radar.
| Company / reporting entity | Revenue | Net profit / loss | Net margin | Revenue growth | Total assets |
|---|---|---|---|---|---|
| A1Plc ↗02690345 | £60.1m | £2.7m | +4.4% | — | — |
| Oviva ↗09667784 | £40.0m | £9.3m | +23.4% | — | — |
| Person Centred Software ↗08539732 | £25.2m | £3.5m | +13.9% | — | — |
| Health and Care ↗08999815 | £20.7m | £-0.4m | -2.0% | — | — |
| LabLogic Systems ↗02062398 | £14.8m | £3.1m | +20.7% | — | — |
| Teleta Pharma ↗06800217 | £13.3m | £0.7m | +5.5% | — | — |
| Streets Heaver Healthcare Computing ↗01999298 | £6.9m | £0.9m | +12.7% | — | — |
| Patient Pass ↗11991272 | Financial figure available in Radar | Financial figure available in Radar | Financial figure available in Radar | Financial figure available in Radar | Financial figure available in Radar |
Explore full company accounts and filings.
Choose “View accounts” to inspect an available company preview.
Each pair uses the same year, currency and reporting basis. Cohort overlap is disclosed.
| Industry | Covered / eligible | Revenue total | Median revenue | Net profit / loss | Aggregate margin | Profitable share | Overlap |
|---|
Available-account cohorts are not estimates of whole industries. Overlapping entities can occur in more than one cohort; do not add cohort totals.
Filed annual accounts for exact designated national identifiers. Every aggregate and peer pair uses one fiscal year, source currency and reporting basis; periods, coverage and overlap are explicit; 2026 partials are excluded.
The same up to eight reporting entities remain open across years, filters and sorts. Other company figures are available in Radar.
Source currencies and accounting bases stay separate. Missing accounts are excluded rather than treated as zero. Exact reporting periods appear on company previews. Annual totals can change with coverage and do not measure growth of a fixed company cohort.
How the the United Kingdom companies on this page show up online: the sites people visit, the apps they install, and how often those apps ship.
65 of the 5,682 companies on this page carry a measured traffic record (1.1%); these are the largest of those, by monthly visits. The median among them is 272,224 visits.
| Company | Monthly visits | Authority | Mobile |
|---|---|---|---|
| TPPtpp-uk.com | 7,005,826 | 51 | 83.8% |
| Holland & Barretthollandandbarrett.com | 5,631,271 | 67 | 80.4% |
| Floflo.health | 5,110,217 | 68 | 93.5% |
| DrDoctordrdoctor.co.uk | 3,391,121 | 37 | 94.6% |
| Doktorabcdoktorabc.com | 3,053,124 | 49 | 83.5% |
| MedExpressmedexpress.co.uk | 2,764,662 | 51 | 94.1% |
| Patients Know Bestpatientsknowbest.com | 2,213,374 | 40 | 85.4% |
| Pharmacy2Upharmacy2u.co.uk | 2,130,622 | 54 | 83.7% |
| Passmedicinepassmedicine.com | 1,614,422 | 37 | 8.2% |
| Animaanimahealth.com | 1,554,278 | 43 | 95.7% |
Visits and authority are third-party web estimates, not company-reported figures.
621 of these companies (10.9%) publish at least one Android app — 999 apps in all, carrying 412.1M installs between them.
| App | Installs | Rating | Store category |
|---|---|---|---|
| Flo Ovulation & Period TrackerFlo | 198.7M | 4.7 | Health & Fitness |
| Pregnancy + | Tracker AppHealth & Parenting | 57.7M | 4.8 | Parenting |
| Peak – Brain Games & TrainingPeak | 29.4M | 4.4 | Education |
| Pregnancy Tracker: ammaamma | 24.4M | 4.6 | Parenting |
| NHS AppNHS Choices | 22.6M | 3.4 | Medical |
| Baby + | Your Baby TrackerHealth & Parenting | 7.6M | 4.6 | Parenting |
| SnoreLab : Record Your SnoringSnoreLab | 7M | 4.4 | Health & Fitness |
| Smoke Free - quit smoking nowSmoke Free | 3.3M | 4.7 | Health & Fitness |
| PhysiApp®PhysiApp | 3.3M | 4.8 | Health & Fitness |
| Patient AccessPatient Access | 3.2M | 4.6 | Medical |
Installs are lifetime totals to date at the June 2026 store reading — a measure of reach, not of people using an app today.
The busiest app inside each of this page’s own segments, with the quarterly release trend behind it (2024Q1–2026Q2).
| Segment | Apps | Installs | Leading app | Release trend |
|---|---|---|---|---|
| Disease Self Management | 293 | 351.9M | Flo Ovulation & Period Tracker 198.7M | |
| Online Health Information | 17 | 54.4M | Pregnancy Tracker: amma 24.4M | |
| Healthcare Booking Platforms | 155 | 41.3M | NHS App 22.6M | |
| Continued Learning | 25 | 32.3M | Peak – Brain Games & Training 29.4M | |
| Healthcare It | 578 | 24.2M | PhysiApp® 3.3M | |
| Fitness & Wellness Tech | 74 | 18M | SnoreLab : Record Your Snoring 7M | |
| Mom & Baby Care | 5 | 3.7M | Moshi Kids: Sleep, Relax, Play 2M | |
| Pre-K Edtech | 3 | 3.7M | Moshi Monsters Egg Hunt 1.1M |
A company can carry several segment tags, so these rows overlap and should not be added together. Trend lines are zero-based and share one quarter grid, so a flat line is a quiet segment, not a missing one.
New apps published, beside apps whose most recent update landed in that quarter — the second bar is how much of the shelf is still being maintained.
Darker bars are new releases, lighter bars apps updated. 752 of 999 apps carry a release date. The series ends at 2026Q1, the last quarter that closed before the June 2026 reading.
Explore the segments behind the headline numbers.
Rank segments by scale, hiring or disclosed funding.
Companies can sit in several segments. Counts and funding overlap.
The largest measured segment in this report snapshot.
117 companies hiring · $10.41B disclosed funding
Explore in RadarCommon revenue models; a company can use more than one.
Recorded corporate activity linked to companies in this landscape.
In 2022, Spirit entered a $7.6 billion merger agreement under which JetBlue would acquire it, effectively establishing the fifth-largest carrier in the country.
A university spinout which specialises in hyperspectral imaging to assist surgeons has clinched a £17m funding boost from investors including London-listed IP Group.
PlaqueTec, a medtech company pioneering intracoronary liquid biopsy to identify inflammatory drivers of cardiovascular disease, has raised $5 million.
Advanced Medical Solutions said on Monday that it is in negotiations with U.S. private equity firm TA Associates over a potential takeover of the British medical supplier.
Creo Medical Group has entered into an agreement to sell its manufacturing operations to Creo’s current manufacturing operations management as a management buyout for an undisclosed amount.
EKF Diagnostics has acquired technology assets from Beep Insights, a developer of sports performance management mobile applications.
H.I.G. Capital-backed Vernacare has acquired Cardiff-based Eakin Surgical from Eakin Healthcare Group.
Advanced skincare and cosmetics company Corryn Biotechnologies has secured a £500,000 equity investment to support commercialisation and scale-up of its cosmetic aftercare products in the UK and US.
Venus Concept Inc. (“Venus Concept” or the “Company”), a global medical aesthetic technology leader, today announced the successful completion by affiliates of Madryn Asset Management, LP (“Madryn”) of a short-form merger transaction, pursuant to which 100% ownership of the Company’s common stock is now consolidated under funds managed by Madryn (the “Short-form Merger”).
Marsden Group chief executive Sajad Bassam has been appointed chief executive of the combined group, and said the merger was about building a platform for strategic long-term growth in New Zealand.
Top 10 categories among 765 recorded events in the 24-month window.
5 companies with recorded IPO activity
IPO · Hong Kong Stock Exchange2 reports
Follow-on Offering · AIM1 reports
IPO · London Stock Exchange3 reports
IPO · Nasdaq4 reports
IPO1 reports
39 tracked people moves
Appointment Interim Chief Executive Officer
Retirement Previously Board member
Appointment Chief Financial Officer
Appointment Chairman
Resignation Previously Chairman
Departure Previously CFO and director
Appointment Chief Executive Officer
Promotion Technical Development Manager
Products, platforms and features in the recorded window
Warehouse automation
Feature
Imaging
Feminine care
AI Agent
Robot Technology Platform
Orthodontic AI education tool and clinical coach
Patient-friendly note generation tool
7 recorded customer wins
Customer: Medical diagnostics
Customer: bootsHealthcare
Customer: Cizzle BioHealthcare diagnostics
Customer: St Mark’s HospitalHealthcare
Customer: Microsoft Azure MarketplaceTechnology
Customer: nipro corporationPharmaceuticals/Medical Devices
2 companies with reported reductions
93 rolesbusiness downturn
Scale not stated roles
8 recorded events
approved for useNew York State Department of Health
approved for tradingLondon Stock Exchange
anticipated FDA clearance by 2027FDA
5 tracked suits
antitrust merger enforcementAntitrust · Settled
antitrust merger challengeAntitrust · Filed
Reported company results in the recorded window.
Median across 102 reported growth observations; companies may contribute multiple periods.
Company-linked deal reports; status is preserved as recorded.
| Acquirer → target | Status | Date | Value / context |
|---|---|---|---|
| jetblue→Spirit ↗ | Terminated | 2026-05-04 | $7.6B |
| ta associates→Advanced Medical Solutions ↗ | Rumored | 2026-04-21 | Not stated in snapshot |
| EKF→Beep insights | Announced | 2026-04-16 | Not stated in snapshot |
| newco→Creo Medical ↗ | Announced | 2026-04-16 | Not stated in snapshot |
| vernacare→Eakinsurgical ↗ | Announced | 2026-04-09 | Not stated in snapshot |
| madryn asset management→Venus Concept ↗ | Completed | 2026-03-30 | Not stated in snapshot |
A discussion or rumour is not a completed transaction. An unstated value is not zero.
152 postings in the preceding 12 months. The full 486-posting snapshot covers 27 employers.
13 tracked postings mention remote work.
3 postings specify a level.
Top skills across 486 tracked postings in the available jobs snapshot.
| Company | Open roles |
|---|---|
| LivaNova ↗ | 11 |
| mobius mobility ↗ | 7 |
| Amber Therapeutics ↗ | 6 |
| PicturaBio ↗ | 6 |
| OrganOx ↗ | 6 |
| Zava ↗ | 5 |
| Randox ↗ | 5 |
| Terumo Aortic ↗ | 5 |
| Company | Employees |
|---|---|
| Smith+Nephew ↗ | 18,976 |
| NHS Choices ↗ | 7,997 |
| Bespak ↗ | 2,000 |
| scapa group ↗ | 1,594 |
| Kent Community Health NHS Foundation Trust ↗ | 1,482 |
| ConvaTec Group ↗ | 971 |
| Epredia ↗ | 863 |
| Advanced Medical Solutions ↗ | 719 |
2,607 founders and chief executives across 1,959 companies.
University of the Witwatersrand MB, University of Cape Town, University of Cambridge MA
BuildingMinds, Cera, ex-XOM Materials, McKinsey. Czech Technical University in Prague BASc 2009, Johannes Kepler University Linz MSc 2011
Ex-MannKind, Medtronic, GE Healthcare, GE Appliances. Indiana University Bloomington MBA 2004, MS 2005
Ex-raks, Mondus, Reha · University of Oxford DPhil 1999
Founder Flo Health, Prisma Labs, ex- Co-Founder IDEAnomix Digital, IDEAnomix, AIMatter, Mail.Ru Group…
University of Cambridge ME 2001
Gamida Cell, Arrowhead Research, ex-Novartis, Bay City Capital, Systemix. University of Guelph BSc 1982, PhD 1986
Ucl, ex-Inivata, ex-University Of Birmingham, University of Birmingham, 1970
Architectural Association, ex- Zaha Hadid Architects. American University of Sharjah BArch 2008, Architectural Association MArch 2010
Numan Com, ex-Personal, ex-Togethera And Upshot, King's College London, U. of London, 2002
Elvie, ex-Prosiebensat 1 Media, ex-Dyson, Wirtschaftsuniversität Wien, 1994
Creo Medical, ex-Cloud Amber, ex-Acis, UCNW, 1993
474 profiles with education records.
52 profiles with prior-work records.
Profiles cover recorded founders and leaders; contact details remain in Radar.
634,583 articles in the measured 12-month window.
Healthtech coverage across United Kingdom · articles per complete quarter
| Quarter | Articles |
|---|---|
| 2021Q2 | 84,657 |
| 2021Q3 | 89,977 |
| 2021Q4 | 81,949 |
| 2022Q1 | 87,308 |
| 2022Q2 | 78,983 |
| 2022Q3 | 78,646 |
| 2022Q4 | 90,051 |
| 2023Q1 | 90,551 |
| 2023Q2 | 91,265 |
| 2023Q3 | 99,643 |
| 2023Q4 | 87,779 |
| 2024Q1 | 99,208 |
| 2024Q2 | 104,734 |
| 2024Q3 | 104,656 |
| 2024Q4 | 113,889 |
| 2025Q1 | 162,472 |
| 2025Q2 | 114,886 |
| 2025Q3 | 353,540 |
| 2025Q4 | 75,834 |
| 2026Q1 | 101,045 |
Article volume measures coverage, not market sales.
1,101 recorded company events across 202 companies; percentages use that event total.
Healthtech coverage across United Kingdom · ranked by full-period article count.
Recent and prior counts use the source comparison windows.
Healthtech coverage across United Kingdom
| Keyword | Recent | Prior | Change |
|---|---|---|---|
| countries | 4,192 | 1,862 | 125% |
| tariff negotiations | 3,966 | 2,331 | 70% |
| stock performance | 2,379 | 1,589 | 50% |
| free trade deals | 2,155 | 1,036 | 108% |
| trade dispute mechanisms | 1,845 | 776 | 138% |
| bilateral trade | 1,759 | 707 | 149% |
| foreign policy analysis | 1,379 | 908 | 52% |
| multilateral diplomacy | 1,352 | 757 | 79% |
| national security strategy | 1,216 | 511 | 138% |
| exchange rates | 1,081 | 278 | 289% |
| free casino games | 26 | 1,120 | -98% |
| social casino | 26 | 1,117 | -98% |
| sweepstakes casino | 27 | 1,116 | -98% |
| simulated gambling apps | 29 | 1,115 | -97% |
| fun play casinos | 28 | 1,114 | -97% |
Healthtech coverage across United Kingdom
territories, disputed islands, countries
25.4% critical · 15.9% positiveinflation reports fx, currency intervention policies, trade deficits fx
43.2% critical · 42.3% positivegdp growth forex, stock performance, inflation reports fx
29.6% critical · 48.1% positiveHealthtech coverage across United Kingdom. Topic labels describe recorded classifications and can include broad context.
53,214 papers in the recorded worldwide scope.
Tone counts: 46,301 positive · 2,052 neutral · 4,861 negative.
Landmark: Implementation strategies: recommendations for specifying and reporting
Landmark: Deep Learning for Health Informatics
Landmark: Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science
Common problems researchers identify · 0119.0% of this theme group
Examines challenges and strategies for building resilient health care delivery and administration.
Health informatics (400) · Health administration (281) · Nursing research (250) · Public health (273)
Resilient Health Care: a systematic review of conceptualisations, study methods and factors that develop resilience
Health systems resilience in practice: a scoping review to identify strategies for building resilience
| Year | Share index |
|---|---|
| 2022 | 23.2 |
| 2023 | 21.1 |
| 2024 | 27.6 |
| 2025 | 44.8 |
Common problems researchers identify · 0218.9% of this theme group
Highlights difficulties in discovering and repurposing drugs for multifactorial diseases.
Drug discovery (321) · Drug (197) · Drug development (103) · Disease (155)
A perspective on multi‐target drug discovery and design for complex diseases
Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer
| Year | Share index |
|---|---|
| 2022 | 157.3 |
| 2023 | 161.8 |
| 2024 | 169.7 |
| 2025 | 211.5 |
Common problems researchers identify · 0315.9% of this theme group
Discusses barriers to adopting eHealth tools and digital transformation in health care.
Digital health (627) · Health care (357) · Digital transformation (69) · eHealth (97)
Technology and Universal Health Coverage: Examining the role of digital health
Engagement With and Acceptability of Digital Media Platforms for Use in Improving Health Behaviors Among Vulnerable Families: Systematic Rev
| Year | Share index |
|---|---|
| 2022 | 538.7 |
| 2023 | 553.0 |
| 2024 | 540.4 |
| 2025 | 843.9 |
Common problems researchers identify · 0414.7% of this theme group
Analyzes practical and regulatory obstacles to scaling telemedicine and telerehabilitation.
Telemedicine (604) · Telehealth (394) · Health care (334) · Telerehabilitation (53)
Opportunities and challenges for telehealth within, and beyond, a pandemic
Strategies for Evaluating Telehealth
| Year | Share index |
|---|---|
| 2022 | 542.2 |
| 2023 | 554.7 |
| 2024 | 541.1 |
| 2025 | 844.0 |
Common problems researchers identify · 0511.7% of this theme group
Focuses on limits of personalized cancer diagnostics, biomarkers, and drug resistance.
Precision medicine (480) · Personalized medicine (238) · Disease (116) · Precision oncology (28)
Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance
Personalizing Oncology: Perspectives and Prospects
| Year | Share index |
|---|---|
| 2022 | 1255.2 |
| 2023 | 1115.6 |
| 2024 | 1012.0 |
| 2025 | 1296.9 |
Common problems researchers identify · 0610.9% of this theme group
Addresses safety, risk analysis, and regulatory gaps for emerging medical equipment and wearables.
Medical device (221) · Wearable computer (50) · Medical equipment (27) · Risk analysis (34)
Energy sources and their development for application in medical devices
Medical Devices and Health — Creating a New Regulatory Framework for Moderate-Risk Devices
| Year | Share index |
|---|---|
| 2022 | 40.4 |
| 2023 | 42.2 |
| 2024 | 43.7 |
| 2025 | 72.1 |
Common problems researchers identify · 078.8% of this theme group
Explores how COVID‑19 altered telehealth usage and highlighted systemic weaknesses.
Pandemic (394) · Coronavirus disease 2019 (274) · 2019-20 coronavirus outbreak (69) · Telemedicine (258)
Quantifying the Impact of COVID-19 on Telemedicine Utilization: Retrospective Observational Study
Telemedicine Evaluations in Neuro-Ophthalmology During the COVID-19 Pandemic: Patient and Physician Surveys
| Year | Share index |
|---|---|
| 2022 | 655.3 |
| 2023 | 440.6 |
| 2024 | 327.7 |
| 2025 | 212.1 |
Cautions · 0119.8% of this theme group
Calls for careful evaluation of telehealth effectiveness and patient satisfaction.
Telemedicine (762) · Telehealth (476) · Telerehabilitation (118) · Health care (319)
The Role of Telemedicine in Improving Healthcare Outcome: A Review
Assessing the Efficiency and Patient Satisfaction of Telemedicine in Managing Chronic Health Conditions
| Year | Share index |
|---|---|
| 2022 | 51.7 |
| 2023 | 48.4 |
| 2024 | 44.2 |
| 2025 | 63.5 |
Cautions · 0219.8% of this theme group
Warns of technical, infrastructural, and quality‑assessment issues in digital health rollout.
Health informatics (239) · Health administration (157) · Nursing research (113) · Medical device (92)
Challenges of using e-health technologies to support clinical care in rural Africa: a longitudinal mixed methods study exploring primary hea
Development and analysis of quality assessment tools for different types of patient information – websites, decision aids, question prompt l
| Year | Share index |
|---|---|
| 2022 | 23.2 |
| 2023 | 21.1 |
| 2024 | 27.6 |
| 2025 | 44.8 |
Cautions · 0315.3% of this theme group
Notes regulatory and predictive challenges when integrating genetics into drug development.
Drug discovery (202) · Drug (160) · Pharmacogenomics (109) · Pharmacogenetics (64)
Biomarkers: Opportunities and Challenges for Drug Development in the Current Regulatory Landscape
Can We Predict Clinical Pharmacokinetics of Highly Lipophilic Compounds by Integration of Machine Learning or In Vitro Data into Physiologic
| Year | Share index |
|---|---|
| 2022 | 154.6 |
| 2023 | 158.9 |
| 2024 | 165.9 |
| 2025 | 206.7 |
Cautions · 0414.7% of this theme group
Highlights concerns about efficacy, adoption, and user experience of digital mental‑health tools.
Digital health (480) · Psychological intervention (265) · Mental health (159) · Health care (262)
Digital Health Interventions to Enhance Prevention in Primary Care: Scoping Review
Digital Health Interventions for Promoting Healthy Aging: A Systematic Review of Adoption Patterns, Efficacy, and User Experience
| Year | Share index |
|---|---|
| 2022 | 790.2 |
| 2023 | 807.5 |
| 2024 | 810.9 |
| 2025 | 1159.7 |
Cautions · 0511.2% of this theme group
Points out clinician hesitancy and workflow disruptions during pandemic‑driven telemedicine.
Pandemic (431) · Coronavirus disease 2019 (360) · Telemedicine (348) · 2019-20 coronavirus outbreak (77)
Community Mental Health Clinicians’ Perspectives on Telehealth During the COVID-19 Pandemic: Mixed Methods Study
Exploring Ophthalmologists’ Adoption of Telemedicine during the COVID-19 Pandemic: A Mixed Methods Study
| Year | Share index |
|---|---|
| 2022 | 544.1 |
| 2023 | 376.7 |
| 2024 | 243.3 |
| 2025 | 191.2 |
Cautions · 0610.3% of this theme group
Raises issues of awareness, equity, and clinical integration for personalized cancer care.
Precision medicine (249) · Personalized medicine (164) · Cancer (103) · Oncology (57)
Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Sur
Role of Proteins in Oncology: Advances in Cancer Diagnosis, Prognosis, and Targeted Therapy—A Narrative Review
| Year | Share index |
|---|---|
| 2022 | 767.8 |
| 2023 | 1043.6 |
| 2024 | 798.0 |
| 2025 | 771.4 |
Cautions · 078.8% of this theme group
Emphasizes ethical, interpretability, and validation hurdles for AI‑driven precision medicine.
Applications of artificial intelligence (102) · Transformative learning (77) · Health care (188) · Precision medicine (102)
Artificial intelligence in healthcare: revolutionizing precision medicine, predictive analytics, and ethical considerations in autonomous di
Artificial Intelligence in Medicine: Transforming Diagnosis, Treatment, and Healthcare Delivery
| Year | Share index |
|---|---|
| 2022 | 534.7 |
| 2023 | 549.6 |
| 2024 | 538.1 |
| 2025 | 839.2 |
Opportunities · 0118.0% of this theme group
Identifies pathways to improve user‑centered design and clinical integration of digital tools.
Digital health (282) · Health care (348) · Health informatics (142) · Psychological intervention (156)
Development of an Evidence-Based Conceptual Model of the Health Care Sector Under Digital Transformation: Integrative Review
HCI-modelling for improving the clinical usability of digital health technologies
| Year | Share index |
|---|---|
| 2022 | 541.3 |
| 2023 | 554.6 |
| 2024 | 543.2 |
| 2025 | 853.3 |
Opportunities · 0216.6% of this theme group
Shows promise of computational docking and virtual screening for rapid therapeutic discovery.
Drug discovery (282) · In silico (99) · Drug (156) · Docking (85)
Exploring Cimetidine\nas a Potential Therapeutic Attenuator\nagainst Amyloid Formation in Parkinson’s Disease: Spectroscopic\nand Microscopi
Design, Synthesis,\nand Biological Evaluation of 5‑Formyl-pyrrolo[3,2‑<i>b</i>]pyridine-3-carboxamides as New Selective, Potent,
| Year | Share index |
|---|---|
| 2022 | 167.5 |
| 2023 | 172.4 |
| 2024 | 180.4 |
| 2025 | 218.9 |
Opportunities · 0313.8% of this theme group
Highlights advances in modeling chemical space to accelerate drug design pipelines.
Drug discovery (535) · Computational biology (222) · Drug (223) · Chemical space (66)
Assessing molecular docking tools: understanding drug discovery and design
Molecular Docking in Computer-Aided Drug Discovery: A Powerful Tool for Targeted Therapeutics
| Year | Share index |
|---|---|
| 2022 | 281.3 |
| 2023 | 298.1 |
| 2024 | 330.7 |
| 2025 | 367.6 |
Opportunities · 0413.7% of this theme group
Explores new telehealth models for physical therapy and palliative care delivery.
Telemedicine (475) · Telehealth (353) · Telerehabilitation (87) · Physical therapy (75)
Urgent and non-emergent telehealth care for seniors: Findings from a multi-site impact study
Telehealth for the study of palliative care communication: opportunities, methodological challenges, and recommendations
| Year | Share index |
|---|---|
| 2022 | 51.7 |
| 2023 | 48.4 |
| 2024 | 44.2 |
| 2025 | 63.5 |
Opportunities · 0512.7% of this theme group
Advances methods for tailoring treatments based on genetic variation across diseases.
Precision medicine (283) · Personalized medicine (216) · Disease (142) · Pharmacogenomics (61)
Pathways to personalized medicine—Embracing heterogeneity for progress in clinical therapeutics research in Alzheimer's disease
Deep Learning for Precision Medicine: Advancing Personalized Treatment Plans in Oncology
| Year | Share index |
|---|---|
| 2022 | 1255.2 |
| 2023 | 1115.6 |
| 2024 | 1012.0 |
| 2025 | 1296.9 |
Opportunities · 0612.7% of this theme group
Describes emerging wearable and IoT solutions for remote patient surveillance.
Wearable computer (117) · Medical device (84) · Remote patient monitoring (76) · Internet of Things (49)
Wearable technology. Health-care solutions for a growing global population.
IoT Based Effective Wearable Healthcare Monitoring System For Remote Areas
| Year | Share index |
|---|---|
| 2022 | 40.5 |
| 2023 | 42.2 |
| 2024 | 44.3 |
| 2025 | 74.3 |
Opportunities · 0712.5% of this theme group
Focuses on bioinformatic approaches to identify circulating markers for individualized oncology.
Cancer (241) · Precision medicine (207) · Breast cancer (90) · Lung cancer (44)
Bioinformatics-Based Analysis of Circulating Tumor Cells: A Methodological Overview of Personalized Cancer Treatment
[Molecular biomarkers in breast cancer : advances in precision medicine].
| Year | Share index |
|---|---|
| 2022 | 776.6 |
| 2023 | 1055.1 |
| 2024 | 810.2 |
| 2025 | 787.3 |
Orientation shares compared with 25,000 papers in the reference sample.
| Research orientation | This field | Reference sample |
|---|---|---|
| Promising | 29.7% | 36.7% |
| Problem-identifying | 29.0% | 9.9% |
| Descriptive | 18.8% | 17.8% |
| Breakthrough | 12.7% | 26.5% |
| Cautionary | 6.4% | 4.5% |
| Comparative | 2.5% | 3.7% |
| Critical | 0.9% | 0.9% |
Counts and shares refer to the stated research pool. A low count describes how much of that research is recorded here, not the absence of a real-world concern.
| Concern / example paper | Papers | Share | Raised as a problem | Worldwide share |
|---|---|---|---|---|
| Privacy & surveillanceThe future of digital health with federated learning | 4,573 | 2.66% | 2,251 (49.2%) | 2.66% |
| Safety & misuseImpact of Rumors and Misinformation on COVID-19 in Social Media | 292 | 0.17% | 167 (57.2%) | 0.17% |
| Bias & fairnessChallenges and recommendations for wearable devices in digital health: Data quality, interoperability, health equity, fa | 99 | 0.06% | 45 (45.5%) | 0.06% |
| Hardware, e-waste & supply chainE-waste for health: recycling smartphones for health monitoring | 24 | 0.01% | 7 (29.2%) | 0.01% |
| Concentration of compute powerDemonopolizing Medical Knowledge | 16 | 0.01% | 7 (43.8%) | 0.01% |
| Labour & data workNew Work—New Interventions: Digital Occupational Health Interventions and the Co-Creation of a Human-Centered Future of | 11 | 0.01% | 6 (54.5%) | 0.01% |
| Energy & datacenter footprintSUSTAINABLE GREEN COMPUTING FOR MEDICAL APPLICATIONS: ADVANCING RESPONSIBLE HEALTHCARE IT | 10 | 0.01% | 4 (40.0%) | 0.01% |
| Carbon & emissions of computeSustainable AI-Enabled UAV Healthcare Logistics: Environmental, Social, and Governance Implications from a PRISMA-ScR Re | 3 | 0.0% | 1 (33.3%) | 0.0% |
| Water use | 0 | 0.0% | 0 (%) | 0.0% |
Institution and researcher rankings use citations to their covered work. Research scope: worldwide. This may be broader than the company geography.
Published patent filings in the recorded source window.
Compare demand signals in the United Kingdom’s newsflow with the healthtech categories mapped to each signal.
Signal percentile − supply percentile = gap in percentile points. Positive gaps highlight questions to investigate. A high signal can reflect spending pressure or access friction, as well as potential demand.
The comparison is relative to the signal families on this page. A supply percentile of zero means the lowest relative reading, not zero companies. It is a prioritisation clue, not measured market size or unmet demand.
Signal and mapped-supply percentiles, their gap, and change in the signal’s article share.
Swipe horizontally to compare all columns →
| Signal family | Signal percentile | Supply percentile | Relative gap | Gap (points) | Signal share vs prior year |
|---|---|---|---|---|---|
| Infectious outbreaks ↗Disease Burden | 28.6 | 12.5 | +16.1 | +13.7% | |
| Mental health ↗Disease Burden | 78.6 | 75.0 | +3.6 | +41.2% | |
| Air pollution ↗Environmental Driver | 14.3 | 12.5 | +1.8 | +6.7% | |
| Ageing & elder care ↗Disease Burden | 28.6 | 50.0 | -21.4 | +4.8% | |
| Cancer burden ↗Disease Burden | 42.9 | 100.0 | -57.1 | -9.3% | |
| Diabetes, hypertension & cardiac burden ↗Disease Burden | 42.9 | — | No matching category | — | +30.8% |
| Maternal & child health ↗Disease Burden | 71.4 | — | No matching category | — | +33.0% |
| Layoffs & income shocks ↗Spending Pressure | 92.9 | — | No matching category | — | +37.0% |
Showing all 8 signals. Select a family for its history and mapped categories.
All 12 city readings for these demand families in the comparison geography. the United Kingdom is highlighted.
Each city’s reading is a share of its own coverage.
Maternal & child health · Infectious outbreaks · Cancer burden
Maternal & child health · Mental health · Cancer burden
Maternal & child health · Layoffs & income shocks · Cancer burden
Cancer burden · Maternal & child health · Layoffs & income shocks
Mental health · Layoffs & income shocks · Ageing & elder care
Maternal & child health · Cancer burden · Layoffs & income shocks
Cancer burden · Layoffs & income shocks · Maternal & child health
Cancer burden · Layoffs & income shocks · Mental health
Cancer burden · Ageing & elder care · Diabetes, hypertension & cardiac burden
Air pollution · Mental health · Maternal & child health
Layoffs & income shocks · Mental health · Maternal & child health
Maternal & child health · Layoffs & income shocks · Diabetes, hypertension & cardiac burden
Outbreak pressure can pull testing, surveillance and rapid-care demand at short notice.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 74 | 3.34 |
| 2024Q4 | 133 | 6.14 |
| 2025Q1 | 145 | 5.74 |
| 2025Q2 | 120 | 5.94 |
| 2025Q3 | 176 | 7.27 |
| 2025Q4 | 90 | 5.18 |
| 2026Q1 | 114 | 5.75 |
| 2026Q2 | 43 | 4.8 |
Mental-health pressure can pull counselling and tele-psychiatry demand where it surfaces.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 161 | 7.27 |
| 2024Q4 | 222 | 10.25 |
| 2025Q1 | 200 | 7.91 |
| 2025Q2 | 204 | 10.09 |
| 2025Q3 | 362 | 14.95 |
| 2025Q4 | 193 | 11.1 |
| 2026Q1 | 222 | 11.19 |
| 2026Q2 | 99 | 11.05 |
Sustained air-quality stress can pull respiratory and cardiac care demand with it.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 117 | 5.28 |
| 2024Q4 | 115 | 5.31 |
| 2025Q1 | 119 | 4.71 |
| 2025Q2 | 134 | 6.63 |
| 2025Q3 | 188 | 7.77 |
| 2025Q4 | 82 | 4.72 |
| 2026Q1 | 87 | 4.39 |
| 2026Q2 | 51 | 5.69 |
An ageing base can shift demand toward geriatric, home and chronic care.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 128 | 5.78 |
| 2024Q4 | 219 | 10.11 |
| 2025Q1 | 215 | 8.5 |
| 2025Q2 | 186 | 9.2 |
| 2025Q3 | 276 | 11.4 |
| 2025Q4 | 97 | 5.58 |
| 2026Q1 | 163 | 8.22 |
| 2026Q2 | 82 | 9.15 |
Cancer burden can pull screening, diagnostics and oncology capacity demand.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 321 | 14.5 |
| 2024Q4 | 407 | 18.78 |
| 2025Q1 | 533 | 21.08 |
| 2025Q2 | 414 | 20.48 |
| 2025Q3 | 420 | 17.35 |
| 2025Q4 | 307 | 17.66 |
| 2026Q1 | 316 | 15.93 |
| 2026Q2 | 154 | 17.19 |
Chronic cardiometabolic burden can turn into decades of management demand per patient.
This signal has no matching category in the page’s healthtech market map, so no supply percentile or gap is assigned.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 112 | 5.06 |
| 2024Q4 | 106 | 4.89 |
| 2025Q1 | 133 | 5.26 |
| 2025Q2 | 170 | 8.41 |
| 2025Q3 | 182 | 7.52 |
| 2025Q4 | 158 | 9.09 |
| 2026Q1 | 137 | 6.91 |
| 2026Q2 | 60 | 6.7 |
Maternal and child burden can pull immunisation, nutrition and pediatric care demand.
This signal has no matching category in the page’s healthtech market map, so no supply percentile or gap is assigned.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 254 | 11.47 |
| 2024Q4 | 288 | 13.29 |
| 2025Q1 | 242 | 9.57 |
| 2025Q2 | 210 | 10.39 |
| 2025Q3 | 533 | 22.02 |
| 2025Q4 | 169 | 9.72 |
| 2026Q1 | 215 | 10.84 |
| 2026Q2 | 125 | 13.95 |
Layoff cycles can pull discretionary spend back toward value offerings.
This signal has no matching category in the page’s healthtech market map, so no supply percentile or gap is assigned.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 414 | 18.7 |
| 2024Q4 | 385 | 17.77 |
| 2025Q1 | 570 | 22.55 |
| 2025Q2 | 428 | 21.18 |
| 2025Q3 | 663 | 27.39 |
| 2025Q4 | 400 | 23.01 |
| 2026Q1 | 634 | 31.96 |
| 2026Q2 | 243 | 27.12 |
the United Kingdom healthtech coverage
BMJ
1,387 citations in the snapshot
The Lancet
1,270 citations in the snapshot
1,226 citations in the snapshot
BMJ
692 citations in the snapshot
the United Kingdom coverage of this page's demand families
| Keyword | Recent articles | Prior articles | Share change |
|---|---|---|---|
| vaccine misinformation impact | 105 | 23 | 479.2% |
| continuing education immunization | 121 | 27 | 468.6% |
| vaccination-induced herd protection | 86 | 22 | 396.0% |
| pediatric catch-up vaccinations | 189 | 62 | 286.8% |
| exercise oncology | 67 | 47 | 80.9% |
| blood pressure reduction rate | 41 | 30 | 73.4% |
Share changes describe coverage in the stated comparison periods, not search demand or market size.
Company counts, hiring and disclosed funding across the recorded hubs.
72.6% across the displayed hubs
51 companies hiring · $5.9B disclosed funding
Explore companies in London ↗
6.7% across the displayed hubs
11 companies hiring · $2.5B disclosed funding
Explore companies in Cambridge ↗
5.0% across the displayed hubs
5 companies hiring · $209.9M disclosed funding
Explore companies in Manchester ↗
3.7% across the displayed hubs
6 companies hiring · $944.2M disclosed funding
Explore companies in Oxford ↗
3.2% across the displayed hubs
5 companies hiring · $112.5M disclosed funding
Explore companies in Bristol ↗
3.1% across the displayed hubs
3 companies hiring · $250.7M disclosed funding
Explore companies in Edinburgh ↗
3.0% across the displayed hubs
4 companies hiring · $355.2M disclosed funding
Explore companies in Leeds ↗
2.7% across the displayed hubs
3 companies hiring · $134.2M disclosed funding
Explore companies in Glasgow ↗Clear definitions for making better comparisons.
It measures the tracked company ecosystem, recorded funding, hiring and other available evidence. It is not a market-size estimate.
No. A company can belong to several segments, so segment counts and funding can overlap.
A dash or unavailable panel means the current reviewed source snapshot does not support that figure.
Company ecosystem snapshot: 31 August 2026. Funding is recorded in USD; filed accounts retain their stated currency and reporting basis. Each section identifies its own coverage. The news and research behind these sections is explorable in Prism.
Canonical landscape ↗